In the neo-adjuvant setting, the relationship between obesity and response to anti-HER2 agents has been evaluated mainly by retrospective or institutional series, which reported that obesity can independently and negatively affect response rate, including pathological complete response (pCR) [5–7]. The gene discussed is ERBB2; the disease is obesity due to melanocortin 4 receptor deficiency.